Trial Details

Not Recruiting
Basic Information
Clinical ID c5088
Identifier EUCTR2016-003073-18-GB
Trial Title A Phase I, Single-Centre, Single Dose Oral Excretion Balance Study of [14C]-RPC1063 in Healthy Male Adults - ADME study of [14C]-RPC1063 in healthy male subjects (QCL117686)
Trial URL Visit Original Page
Study Information
Study Results

Yes
Conditions The drug is a potential treatment for adult patients with relapsing multiple sclerosis (RMS) and for adult patients with moderately to severely active inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn disease (CD).
Interventions Product Name: [14C]-RPC1063 Solution (0.1 mg/mL) for Oral Administration Pharmaceutical Form: Oral solution INN or Proposed INN: Ozanimod hydrochloride CAS Number: 1618636-37-5<b
Participant Information
Sponsor Celgene International II S??????l
City NULL
Country/Region United Kingdom
Enrollment Criteria
Sex Requirement NOT SPECIFIED
Age Requirement NULL
Study Design
Study Type Interventional clinical trial of medicinal product
Phase PHASE1
Time Information
Start Date NULL
Primary Completion Date NULL
Completion Date NULL